Plain-English translation of NCT07638371 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 safety trial of , a new type of immunotherapy that uses your own immune cells (T-cells) that have been modified in the laboratory to recognize and attack cancer cells with a specific RAS G12D mutation. Researchers at Memorial Sloan Kettering Cancer Center are testing this treatment in people with advanced solid tumors—like colorectal cancer, lung cancer, or pancreatic cancer—that have this particular genetic mutation. The goal is to learn whether this medication is safe and how well it works.
Many solid cancers develop a mutation in the RAS gene that helps them grow and survive standard treatments. This treatment exists because current options have not stopped these cancers from spreading, and doctors need new ways to help patients whose tumors carry this specific mutation.
You likely qualify if…
You likely don't qualify if…
If you qualify, your own T-cells (immune cells) will be collected and sent to the laboratory, where they will be genetically modified to recognize your cancer. While your cells are being prepared, you may receive preparation treatment. Once your modified cells are ready, you will receive the treatment through an infusion. Researchers will monitor you closely with blood tests and imaging scans to watch for side effects and see how your cancer responds. The trial is designed to test different doses in small groups, starting with lower doses and increasing gradually if safety allows.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States